Key result
Surgery plus adjuvant chemotherapy yields 2-year survival in a primary ovarian angiosarcoma case.
Why the study?
Angiosarcomas are rare sarcomas with a poor prognosis and evolving treatments, and those occurring at rare sites have fewer published case reports and series.
Case Report (n=1)
This case report highlights the rare occurrence of primary ovarian angiosarcoma and emphasizes the importance of histological and immunohistochemical workup for accurate diagnosis.
Requires IHC for rare ovarian angiosarcoma in teratoma; extends case literature but leaves management and prognosis open.
Angiosarcomas are rare sarcomas with a poor prognosis, and treatment modalities are still being established. Cutaneous and soft tissue angiosarcomas are frequently reported; however, those occurring at rare sites have fewer published case reports and series. An unusual case was encountered at our institute: a 25-year-old woman with an ovarian tumor in which angiosarcoma was diagnosed in a background of teratoma. The details of surgery, gross appearance, histopathological findings, and immunohistochemistry (IHC) workup leading to the diagnosis are presented, along with a review of the current literature. The ease of reaching the histological diagnosis of angiosarcoma depends on the site of occurrence and degree of differentiation. Recent advances in therapeutics, along with emerging evidence from clinical trials, have demonstrated promising outcomes in the treatment of angiosarcoma. It is possible to reach an accurate diagnosis by keeping in mind its histological variability and key histologic features and by performing an appropriate IHC workup. Improving treatment results for patients with angiosarcoma involves a shift toward multimodal therapy and precision medicine, and recent breakthroughs offer hope for better outcomes.
No takes yet. Share an insight, caveat, or question.
Parmar et al. (2026) conducted a case report in Primary Ovarian Angiosarcoma (n=1). Surgical resection and adjuvant chemotherapy (ifosfamide and Adriamycin) was evaluated on Patient survival. Surgical resection followed by adjuvant chemotherapy with ifosfamide and Adriamycin resulted in the patient remaining alive at two years follow-up for primary ovarian angiosarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: